Immunotherapy improves survival in metastatic or recurrent head and neck cancer
Immunotherapy with pembrolizumab improves survival in patients with head and neck cancer that has recurred or metastasised, according to late-breaking results from the KEYNOTE-048 study reported at the ESMO 2018 Congress ...
Oct 22, 2018
0
1